IP Verse

Anticancer Compositions - EP3226841

The patent EP3226841 was granted to Aragon Pharmaceuticals on Oct 9, 2024. The application was originally filed on Dec 3, 2015 under application number EP15817641A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3226841

ARAGON PHARMACEUTICALS
Application Number
EP15817641A
Filing Date
Dec 3, 2015
Status
Granted And Under Opposition
Sep 6, 2024
Grant Date
Oct 9, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (6)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

BRAND MURRAY FULLERJul 9, 2025ADMISSIBLE
EIPJul 9, 2025ADMISSIBLE
HEXALJul 9, 2025ADMISSIBLE
TEVA PHARMACEUTICALSJul 8, 2025ADMISSIBLE
HAMM & WITTKOPPJul 7, 2025ADMISSIBLE
ZENTIVA KSJul 7, 2025ADMISSIBLE

Patent Citations (21) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2013184681
INTERNATIONAL-SEARCH-REPORTWO2013152342
INTERNATIONAL-SEARCH-REPORTWO2015023710
INTERNATIONAL-SEARCH-REPORTWO2015118015
OPPOSITIONEP3725778
OPPOSITIONEP3811932
OPPOSITIONEP3812378
OPPOSITIONWO02067893
OPPOSITIONWO02080902
OPPOSITIONWO03063821
OPPOSITIONWO2006124118
OPPOSITIONWO2007126765
OPPOSITIONWO2011103202
OPPOSITIONWO2013152342
OPPOSITIONWO2013184681
OPPOSITIONWO2014043208
OPPOSITIONWO2014113260
OPPOSITIONWO2015118015
OPPOSITIONWO2016090098
OPPOSITIONWO2016090101
OPPOSITIONWO2016090105

Non-Patent Literature (NPL) Citations (38) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous, "Abbott Receives US FDA Approval for Hear-Stable Norvir@ (ritonavir) Tablets", Press Release, (20100211), pages 1 - 10, Press Release, (20220328), XP055905823-
OPPOSITION- Anonymous, "Abbott's new Kaletra tablets approved by EC", thepharmaletter, (20060709), thepharmaletter, URL: https://www.thepharmaletter.com/article/abbott-s-new-kaletra-tablets-approved-by-ec, XP093297378-
OPPOSITION- Anonymous, "A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects", Clinical Trials Protocol NCT01911741, (20130730), Clinical Trials Protocol NCT01911741, URL: https://clinicaltrials.gov/ct2/show/NCT01911741, (20220530), XP055925759-
OPPOSITION- Anonymous , "Bioavailability Study of 3 Tablet Formulations vs. Capsule Formulation of JNJ-56021927 in Fasting Healthy Male Participants", NCT02160756, (20250203), pages 1 - 13, XP093297120-
OPPOSITION- Anonymous, "CHMP Assessment Report For Intelence - International Nonproprietary Name: etravirine Procedure No. EMEA/H/C/000900", EMEA, (20080101), pages 1 - 52, EMEA, (20220328), XP055905702-
OPPOSITION- Anonymous, "CHMP assessment report INCIVO (telaprevir) - EMA/CHMP/475470/2011 Committee for Medicinal Products for Human Use (CHMP)", EMA, (20110721), XP093297419-
OPPOSITION- Anonymous, "History of Changes for Study: NCT02123758 A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer", Clinical Trials.gov, (20141202), pages 1 - 12, XP055850235-
OPPOSITION- Anonymous, "History of changes for study : NCT02160756 Bioavailability Study of 3 Tablet Formulations vs. Capsule Formulation of JNJ-56021927 in Fasting Healthy Male Participants", ClinicalTrials.gov Identifier: NCT02160756, (20141113), pages 1 - 5, ClinicalTrials.gov Identifier: NCT02160756, (20220328), XP055905635-
OPPOSITION- Anonymous, "Kalydeco (ivacaftor) EMA Assessment Report", European Medicines Agency, (20110701), pages 1 - 13, European Medicines Agency, (20220328), XP055905838-
OPPOSITION- Anonymous, "New Kaletra Tablets FDA Approved: Abbott Press Release", HIV Articles, (20051031), pages 1 - 3, HIV Articles, (20220328), XP055905753-
OPPOSITION- Anonymous, "Package leaflet: Information for the patient - Xtandi 40 mg film-coated tablets - Xtandi 80 mg film-coated tablets - enzalutamide", Astellas, (20220401), Astellas, URL: https://www.astellas.com/gr/system/files/2022-05/PL-Xtandi%20tabs_cc_EN.pdf, XP093297424-
OPPOSITION- Anonymous, "Package leaflet: Information for the user - Erleada 240 mg film-coated tablets - apalutamide", medicines.org.uk, (20241101), medicines.org.uk, URL: https://www.medicines.org.uk/emc/files/pil.15551.pdf, XP093297427-
OPPOSITION- Anonymous, "Shin-Etsu AQOAT® (HPMCAS)", Pharma Excipients, (20250101), Pharma Excipients, URL: https://www.pharmaexcipients.com/product/aqoat/, XP093297428-
OPPOSITION- Anonymous, "Zelboraf (vemurafenib) EMA Assessment Report", Assessment Report, (20111215), pages 1 - 13, Assessment Report, (20220328), XP055905829-
OPPOSITION- Aragon Pharmaceuticals, Inc., "A Study to Assess the Relative Bioavailability of 7 Test Tablet Formulations of JNJ-56021927 With Respect to the Capsule Formulation of JNJ-56021927 in Healthy Male Participants NCT02031666", Clinical Trials, clinicaltrials.gov, (20161019), Clinical Trials, URL: https://clinicaltrials.gov/study/NCT02031666?term=NCT02031666&rank=1&a=6&tab=history, XP093297374-
OPPOSITION- Chmp, "Everolimus EMA Assessment Report - Procedure No.:EMEA/H/C002311/0000", European Medicines Agency, (20110623), pages 1 - 104, European Medicines Agency, (20220328), XP055905721-
OPPOSITION- D23 - T 377/18-
OPPOSITION- D40 - Patentee’s letter from examination (31 May 2023)-
OPPOSITION- D43a - CV of Thomas Rades-
OPPOSITION- D43 - Declaration of Thomas Rades-
OPPOSITION- D53 - Excerpt of Formulation Diary (www.formulationdiary.com) for apalutamide (retrieved on 10 June 2025)-
OPPOSITION- Kumar P, Chhater Sungh, "A Study on solubility enhancement methods for poorly water soluble drugs", American Journal of Pharmacological Sciences, (20130101), vol. 1, no. 4, pages 67 - 73, XP055850216-
OPPOSITION- Llse Weuts, Frederic Van Dycke,1 Jody Voorspoels,1 Steve De Corl,1 Sigrid Stokbroekx,1 Ruud Leemans, 1 Marcus E. Brewster,1 Dawei Xu,2 Brigitte Segmuller,2 Ya Tsz A. Turner,3 Cuve J. Roberts,3 Martyn C. Davies,3 Sheng Ql,4 Duncan Q.M. Craig,4 Mike Reading4, "Physicochemical Properties of the Amorphous Drug, Cast Films, and Spray Dried Powders to Predict Formulation Probability of Success for Solid Dispersions: Etravirine", J Pharm Sci Jan, (20110101), vol. 100, no. 1, pages 260 - 274, XP055850244-
OPPOSITION- R Kumari, Chandel P, Kapoor A, "Paramount Role of Solid Dispersion in Enhancement of Solubility", Indo Global Journal of Pharmaceutical Sciences, (20130101), vol. 3, no. 1, ISSN 22491023, pages 78 - 89, XP055215886-
OPPOSITION- Rowe R. C., "Hypromellose Acetate Succinate", Handbook of Pharmaceutical Excipients. 6th Ed., PhP, (20120101), pages 377 - 380, XP055925757-
OPPOSITION- William Curatolo ; James A. Nightingale ; Scott M. Herbig, "Utility of Hydroxypropylmethylcellulose Acetate Succinate (HPMCAS) for Initiation and Maintenance of Drug Supersaturation in the GI Milieu", Pharmaceutical Research, Kluwer Academic Publishers-Plenum Publishers, NL, NL , (20090310), vol. 26, no. 6, doi:10.1007/s11095-009-9852-z, ISSN 1573-904X, pages 1419 - 1431, XP019686188
OPPOSITION- Alfred C. F. Rumondor ; Lindsay A. Stanford ; Lynne S. Taylor, "Effects of Polymer Type and Storage Relative Humidity on the Kinetics of Felodipine Crystallization from Amorphous Solid Dispersions", Pharmaceutical Research, Kluwer Academic Publishers-Plenum Publishers, NL, NL , (20091006), vol. 26, no. 12, doi:10.1007/s11095-009-9974-3, ISSN 1573-904X, pages 2599 - 2606, XP019752644
OPPOSITION- Yanbin Huang, Wei-Guo Dai, "Fundamental aspects of solid dispersion technology for poorly soluble drugs", Acta Pharmaceutica Sinica B, Elsevier, (20140201), vol. 4, no. 1, doi:10.1016/j.apsb.2013.11.001, ISSN 2211-3835, pages 18 - 25, XP055497465
OPPOSITION- Konno, H. ; Handa, T. ; Alonzo, D.E. ; Taylor, L.S., "Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine", European journal of pharmaceutics and biopharmaceutics, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM., NL, NL , (20081001), vol. 70, no. 2, doi:10.1016/j.ejpb.2008.05.023, ISSN 0939-6411, pages 493 - 499, XP025470891
OPPOSITION- Venecia Wilson, Xiaochun Lou, Donald J. Osterling, Deanne F. Stolarik, Gary Jenkins, Wenqing Gao, Geoff G.Z. Zhang, Lynne S. Taylor, "Relationship between amorphous solid dispersion in vivo absorption and in vitro dissolution: phase behavior during dissolution, speciation, and membrane mass transport", Journal of Controlled Release, Elsevier, NL, NL , (20181201), vol. 292, doi:10.1016/j.jconrel.2018.11.003, ISSN 0168-3659, pages 172 - 182, XP055748090
OPPOSITION- LEUNER CHRISTIAN , DRESSMAN JENNIFER, "Improving drug solubility for oral delivery using solid dispersions.", European journal of pharmaceutics and biopharmaceutics, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM., NL, NL , (20000701), vol. 50, no. 1, doi:10.1016/S0939-6411(00)00076-X, ISSN 0939-6411, pages 47 - 60, XP002155099
OPPOSITION- Dwayne T. Friesen, Ravi Shanker, Marshall Crew, Daniel T. Smithey, W. J. Curatolo, J. A. S. Nightingale, "Hydroxypropyl Methylcellulose Acetate Succinate-Based Spray-Dried Dispersions: An Overview", Molecular Pharmaceutics, American Chemical Society, (20081201), vol. 5, no. 6, doi:10.1021/mp8000793, ISSN 15438384, pages 1003 - 1019, XP055056966
OPPOSITION- Tanno Fumié; Nishiyama Yuichi; Kokubo Hiroyasu; Obara Sakaé, "Evaluation of hypromellose acetate succinate (HPMCAS) as a carrier in solid dispersions.", Journal Drug Development and Industrial Pharmacy, NEW YORK, NY, US, US , (20040101), vol. 30, no. 1, doi:10.1081/DDC-120027506, ISSN 0363-9045, pages 9 - 17, XP009124621
OPPOSITION- H. D. Williams, N. L. Trevaskis, S. A. Charman, R. M. Shanker, W. N. Charman, C. W. Pouton, C. J. H. Porter, "Strategies to Address Low Drug Solubility in Discovery and Development", Pharmacological Reviews, (20130203), vol. 65, no. 1, doi:10.1124/pr.112.005660, pages 315 - 499, XP055157770
OPPOSITION- Clegg N J, Wongvipat J, Joseph J D, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff E D, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert M R, Bonnefous C, Darimont B, Scher H I, Smith-Jones P, Klang M, Smith N D, De Stanchina E, Wu N, Ouerfelli O, Rix P J, Heyman R A, Jung M E, Sawyers C L, Hager J H, "ARN-509: a novel antiandrogen for prostate cancer treatment.", Cancer research, University of Chicago Press, (20120315), vol. 72, no. 6, doi:10.1158/0008-5472.CAN-11-3948, ISSN 0008-5472, pages 1494 - 1503, XP002756285
OPPOSITION- Rathkopf Dana E; Morris Michael J; Fox Josef J; Danila Daniel C; Slovin Susan F; Hager Jeffrey H; Rix Peter J; Chow Maneval Edna; Chen Isan; Goenen Mithat; Fleisher Martin; Larson Steven M; Sawyers Charles L; Scher Howard I, "Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.", Journal of Clinical Oncology, (20131001), vol. 31, no. 28, doi:10.1200/JCO.2013.50.1684, pages 3525 - 3530, XP008166079
OPPOSITION- Yu Fang, Et Al., "Eudragit L/HPMCAS Blend Enteric-Coated Lansoprazole Pellets: Enhanced Drug Stability and Oral Bioavailability", AAPS PharmSciTech, (20140601), vol. 15, no. 3, doi:10.1208/s12249-013-0035-1, pages 513 - 521, XP055377428
OPPOSITION- Sandrien Janssens, Van Den Mooter Guy, "Review: physical chemistry of solid dispersions", Journal of Pharmacy and Pharmacology, (20091201), vol. 61, no. 12, doi:10.1211/jpp/61.12.0001, ISSN 00223573, pages 1571 - 1586, XP055023760

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents